Tier One Advisory LLC的动态

The acquisition of sedApta Group marks a significant milestone in Elisa IndustrIQ's growth trajectory. This move substantially enhances our market presence and capabilities with €50 million in annual revenue and 1,500 customers. It's particularly noteworthy how this acquisition transforms our footprint in Brazil, France, Italy, and the UK - markets where we've been eager to expand our influence. Moreover, this integration builds upon the synergies we've already established, for example, in Germany and the Nordic regions. Our complementary expertise and market focus promise to yield robust opportunities for innovation and service enhancement. For industry analysts tracking the manufacturing software space, this development underscores Elisa IndustrIQ's commitment to becoming a truly global player. We're growing, both in size and our ability, to address diverse market needs across multiple geographies, adding to the North American footprint of?CalcuQuote?and?Romaric Corporation and the established Asia Pacific success of camLine and Elisa Polystar. I look forward to engaging with the analyst community to discuss how this strategic move will shape the future of digital manufacturing solutions. #IndustryAnalysis #MarketExpansion #ManufacturingTech

"If you want to go fast, go alone. If you want to go far, go together.” – This timeless proverb perfectly reflects our philosophy at Enterosys. Our team-building sessions are more than just moments of connection—they are opportunities to strengthen our cohesion, deepen our shared commitment, and align ourselves with a common vision: delivering innovative and reliable preclinical solutions to our clients! ?? Precision, passion, and trust are at the core of everything we do, and a united team is the foundation that makes it all possible. ?? What’s your secret to building a high-performing team? Share your tips with us in the comments below! ?? Together, let’s continue advancing science—one breakthrough at a time. ???

At its Investor Update 2024, Lonza announced an organizational restructuring. The move aims to protect and enhance key Lonza business strengths. ?? https://hubs.li/Q02_NFRD0 #pharmanews #Lonza #CDMO https://hubs.li/Q02_NFRD0

A couple of weeks ago Illumina filed a motion to dismiss the major "Kangas" suit against Illumina executives and directors. There's a lot in there - it's about 40 pages of defensive arguments - but the argument I find most cynical is that statements on the lives to be saved by GRAIL by Illumina executives and board members were simply "puffery". In a legal context "puffery" refers to exaggerated statements made by sellers to promote their products or services. For example, a restaurant advertising its dish as “the best pizza in the world” is engaging in puffery. Courts generally consider puffery be viewed as opinions that no reasonable person would rely upon as factual assertions. Here are examples of statements by Illumina executives that Illumina now claims were simple puffery: "statements that the merger would “save lives”" "statements that the merger would “dramatically accelerate getting this test into the hands of people whose lives it could save"" "statements that the merger would enable Illumina to bring Galleri to “patients across the world faster and consequently save lives” So, Illumina itself is now admitting that everything they said about GRAIL saving lies was just bullshit. That's their defense. No shame. ??????

"Happy 6th Company Anniversary! ???? Today marks another milestone in our journey together. From humble beginnings to remarkable achievements, each step has been a testament to our collective dedication and hard work. We have conquered challenges, celebrated victories, and grown stronger as a team/company with learning experiences and customer feedbacks. We continue to innovate, inspire, and exceed expectations in the years ahead. Welcome many more successes together! Cheers to us! ?? #TeamSuccess #6thAnniversaryCelebration"

In late 2022, Norstella completed it merger with Citeline, creating the world’s largest pharma intelligence provider. Now, Norstella is harnessing Citeline’s solutions to accelerate drug development and get therapies to patients faster. Explore what happened when Norstella enlisted the help of GlobalLogic to migrate its AWS infrastructure under a 4-month deadline: https://lnkd.in/eGgVSZdy #Norstella #Citeline #PharmaIntelligence #PharmaTech #AWS

?????? ??&?? ??????????-??????? Q2 2024 brought with some big hits in the M&A world, from the sheer size of acquisitions (Johnson & Johnson/Shockwave Medical) to the ones that nobody saw coming (Hologic, Inc./ Endomag). ???????? ?????? ???????? ???? ?????? ?????????? ???????? ?????? ?????? ?????????????????? ???????? ??????????????: ?? Johnson & Johnson acquisition of Shockwave Medical for $13 Bil ?? Peak Rock Capital (PE) acquisition of HuFriedyGroup (part of STERIS) for $788 Mil ♀? Hologic, Inc. acquisition of Endomag for $310 Mil ?? Medline Industries, LP acquisition of Ecolab's #Surgical Division for $950 Mil ?? Nordson Corporation acquisition of Atrion Corp for $800 Mil ?? GTCR LLC (PE) acquisition of Surmodics, Inc. for $627 Mil ?? BD acquisition of Edwards Lifesciences #CriticalCare division for $4.2 Bil Will H2 of the year shape up to be even BIGGER? Watch this space! #medicaldevice #medtech #mergersandacquisitions #executivesearch #recruitment #industrynews #manda #johnsonandjohnson #healthtech

The recent week in the global M&A market showcased significant strategic consolidations despite an overall decline in activity. With 611 deals totaling USD 30.10 billion, the market experienced an 8% drop in deal volume and a substantial 22.3% decrease in total value compared to the previous week. However, large transactions dominated the landscape, particularly in the packaging and defense sectors. A highlight was Amcor plc's landmark USD 8.4 billion all-stock acquisition of Berry Global, positioning the merged entity as a global leader in sustainable packaging solutions for consumer and healthcare markets. This move aligns with ongoing consolidation trends in the packaging industry, as seen with International Paper and Smurfit Kappa's recent deals. Similarly, AeroVironment's USD 4.1 billion acquisition of BlueHalo underscores the defense sector's focus on enhancing technological capabilities and expanding into emerging markets. Other notable deals include Protective Industrial Products' acquisition of Honeywell’s PPE business for USD 1.33 billion, reinforcing its global PPE portfolio, and DT Midstream's USD 1.2 billion purchase of strategic natural gas pipelines, highlighting continued consolidation in the energy sector. Additionally, Novartis AG's USD 1.1 billion acquisition of Kate Therapeutics emphasizes the pharmaceutical industry's commitment to advancing gene therapy technologies. Overall, these transactions reflect strategic efforts to enhance market position, diversify offerings, and drive innovation across various industries, despite a temporary slowdown in broader M&A activity. As the end of the year draws closer, diligently monitoring M&A deals is essential for capturing emerging market trends, identifying strategic opportunities, and ensuring informed decision-making. Let's all keep a close eye on all these deals that round up the year. There seems to be a bit of a slowdown as both deal volume and value have decreased compared to the previous week. Do you think this trend will continue or will things still pick-up? Let all continue to monitor and see how things will continue to shape up. https://lnkd.in/dxKmYNNm #IMAA #MergersAndAcquisitions #MegaDeals #Valuation #PrivateEquity #EntertainmentIndustry #Leadership

Jubilant Biosys Expands Global Footprint with Acquisition of 80% Stake in French R&D Firm JASMIN Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), a subsidiary of Jubilant Biosys Limited, has announced a significant strategic move by entering into definitive agreements with Pierre Fabre SA and its affiliates. The agreement will see JBIRSPL acquire an 80% equity stake in JASMIN, a newly established company in France, while Pierre Fabre retains the remaining 20%. Upon completion, JASMIN will take over Pierre Fabre's Research and Development Centre, including its facilities and ongoing R&D activities located in Saint Julien, France. In conjunction with the acquisition, JBIRSPL will also finalize a Shareholders’ Agreement and other transition agreements with Pierre Fabre, marking a significant step in the company's expansion strategy in the European market.

What our clients say about us ?? At Enterosys, we take pride in combining scientific rigor with adaptability to meet the unique challenges of every client. One of our biotech partners shared their satisfaction with our rigorous experimental management and high-quality reporting during a pilot study. Their experience led to a deeper collaboration—a testament to our commitment to excellence. Beyond the science, we value building strong relationships. For us, being adaptable and responsive is just as important as delivering innovative solutions. ?? What’s the most important quality you look for in a research partner? Share your thoughts below! #ClientFeedback #PreclinicalResearch #ScientificExcellence #Innovation?